{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '-', '205678', 'Reporting of SAE to GSK', 'SAE Reporting to GSK via Electronic Data Collection Tool', 'The primary mechanism for reporting SAE to GSK will be the electronic data', 'collection tool.', 'If the electronic system is unavailable, then the site will use the paper SAE data', 'collection tool (see next section) in order to report the event within 24 hours.', 'The site will enter the SAE data into the electronic system as soon as it becomes', 'available.', 'The investigator or medically-qualified sub-investigator must show evidence within', 'the eCRF (e.g., check review box, signature, etc.) of review and verification of the', 'relationship of each SAE to IP/study participation (causality) within 72 hours of SAE', 'entry into the eCRF.', 'After the study is completed at a given site, the electronic data collection tool will be', 'taken off-line to prevent the entry of new data or changes to existing data.', 'If a site receives a report of a new SAE from a study participant or receives updated', 'data on a previously reported SAE after the electronic data collection tool has been', 'taken off-line, then the site can report this information on a paper SAE form (see', 'next section).', 'Contacts for SAE reporting can be found in SRM.', 'SAE Reporting to GSK via Paper CRF', 'Facsimile transmission of the SAE paper CRF is the preferred method to transmit', 'this information to the SAE coordinator. Details provided in the SRM.', 'In rare circumstances and in the absence of facsimile equipment, notification by', 'telephone is acceptable with a copy of the SAE data collection tool sent by overnight', 'mail or courier service.', 'Initial notification via telephone does not replace the need for the investigator to', 'complete and sign the SAE CRF pages within the designated reporting time frames.', 'Contacts for SAE reporting can be found in the SRM.', '121']['2017N330177_04', 'CONFIDENTIAL', '205678', '12.5.', 'Appendix 5: Contraceptive Guidance and Collection of', 'Pregnancy Information', 'Definitions', 'Woman of Childbearing Potential (WOCBP)', 'A woman is considered fertile following menarche and until becoming post-menopausal', 'unless permanently sterile (see below).', 'If fertility is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle', 'cannot be confirmed before first dose of study intervention, additional evaluation should', 'be considered.', 'Women in the following categories are not considered WOCBP', '1', 'Premenarchal', '2', 'Premenopausal females with ONE of the following:', 'Documented hysterectomy', 'Documented bilateral salpingectomy', 'Documented bilateral oophorectomy', 'For individuals with permanent infertility due to an alternate medical cause', 'other than the above, (e.g., mullerian agenesis, androgen insensitivity),', 'investigator discretion should be applied to determining study entry.', \"Note: Documentation can come from the site personnel's: review of participant's\", 'medical records, medical examination, or medical history interview.', '3', 'Postmenopausal females', 'A postmenopausal state is defined as no menses for 12 months without an', 'alternative medical cause. A high follicle stimulating hormone (FSH) level in', 'the postmenopausal range may be used to confirm a postmenopausal state in', 'women not using hormonal contraception or hormonal replacement therapy', '(HRT). However, in the absence of 12 months of amenorrhea, confirmation with', 'more than one FSH measurement is required.', 'Females on HRT and whose menopausal status is in doubt will be required to', 'use one of the non-estrogen hormonal highly effective contraception methods if', 'they wish to continue their HRT during the study. Otherwise, they must', 'discontinue HRT to allow confirmation of postmenopausal status before study', 'enrollment.', '122']['2017N330177_04', 'CONFIDENTIAL', '205678', 'Contraception Guidance', 'CONTRACEPTIVES ALLOWED DURING THE STUDY INCLUDE:', 'Highly Effective Methodsb That Have Low User Dependency', 'Implantable progestogen-only hormone contraception associated with inhibition of ovulation', 'Intrauterine device (IUD)', 'Intrauterine hormone-releasing system (IUS)c', 'Bilateral tubal occlusion', 'Vasectomized partner', 'Note: Vasectomized partner is a highly effective contraceptive method provided that the partner is the sole', 'sexual partner of the woman of childbearing potential and the absence of sperm has been confirmed. If', 'not, an additional highly effective method of contraception should be used. Spermatogenesis cycle is', 'approximately 90 days.', 'Highly Effective Methodsb That Are User Dependent', 'Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of', 'ovulation', 'oral', 'intravaginal', 'transdermal', 'injectable', 'Progestogen-only hormone contraception associated with inhibition of ovulation\u00b0', 'oral', 'injectable', 'Sexual abstinence', 'Note: Sexual abstinence is considered a highly effective method only if defined as refraining from', 'heterosexual intercourse during the entire period of risk associated with the study intervention. The', 'reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the', 'preferred and usual lifestyle of the participant', 'a.', 'Contraceptive use by men or women should be consistent with local regulations regarding the use of', 'contraceptive methods for those participating in clinical studies.', 'b.', 'Failure rate of <1% per year when used consistently and correctly. Typical use failure rates differ from those when', 'used consistently and correctly.', 'C.', 'Male condoms must be used in addition to hormonal contraception. If locally required, in accordance with Clinical', 'Trial Facilitation Group (CTFG) guidelines, acceptable contraceptive methods are limited to those which inhibit', 'ovulation as the primary mode of action.', 'Note: Periodic abstinence (calendar, sympto-thermal, post-ovulation methods), withdrawal (coitus interruptus),', 'spermicides only, and lactational amenorrhea method (LAM) are not acceptable methods of contraception for this', 'study. Male condom and female condom should not be used together (due to risk of failure with friction)', 'Collection of Pregnancy Information', 'Male participants with partners who become pregnant', \"Investigator will attempt to collect pregnancy information on any male participant's\", 'female partner of a male study participant who becomes pregnant while participating', 'in this study. This applies only to male participants who receive study intervention.', '123']\n\n###\n\n", "completion": "END"}